Oncorus (Oncorus) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Oncorus Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Oncorus is: No Data: Cannot be evaluated.

Competitive Comparison of Oncorus's Risk Assessment

For the Biotechnology subindustry, Oncorus's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncorus's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncorus's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Oncorus's Risk Assessment falls into.

Oncorus (OTCPK:ONCR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Oncorus Risk Assessment Related Terms

Thank you for viewing the detailed overview of Oncorus's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncorus (Oncorus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Corporate Drive, Andover, MA, USA, 01810

Website

https://www.oncorus.com

Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.

Executives

Brian J. Shea	officer: Interim CEO	C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte	officer: Interim CFO	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn	director, 10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough	director	C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall	officer: CFO and Treasurer	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin	officer: COO and Chief of Staff	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin	director	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva	officer: CSO and SVP, Research	C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116